PCSK9: a promising therapeutic target for dyslipidemias?
PCSK9 is the third gene to be implicated in autosomal dominant hypercholesterolemia. The recent discovery of mutations in PCSK9 protein associated with low plasma low-density lipoprotein in humans, the characterization of PCSK9-deficient mice hypersensitive to statins and the severely pathological phenotype of D374Y PCSK9-mutated patients shed a new light on this gene: is it a promising therapeutic target for dyslipidemias?
University of Nantes, Medical School, INSERM U539, CHU Hôtel-Dieu, 3(e) Nord, 1 Place Alexis Ricordeau, F-44093 Nantes cedex 1, France. gilles.lambert@univ-nantes.fr
Gilles
G
Lambert
Michel
M
Krempf
Philippe
P
Costet
D000818:Animals; D020022:Genetic Predisposition to Disease; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000235:genetics; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D051379:Mice; D009154:Mutation; D010641:Phenotype; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D011973:Receptors, LDL / Q000502:physiology; D012697:Serine Endopeptidases / Q000172:deficiency / Q000235:genetics* / Q000502:physiology*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011973:Receptors, LDL; C472125:PCSK9 protein, human; C472126:Pcsk9 protein, mouse; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases